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Background: Seaweeds have a long history of use in Asian countries as functional foods, medicinal herbs, and the
treatment of cancer. Polysaccharides from various seaweeds have shown anti-tumor activity.
Cholangiocarcinoma (CCA), often with metastatic disease, is highly prevalent in Thailand as a consequence of
liver ﬂuke infection. Recently, we extracted sulfated galactans (SG) from Gracilaria ﬁsheri (G. ﬁsheri), a south east
Asian seaweed, and found it exhibited anti-proliferation eﬀect on CCA cells.
Purpose: In the present study, we evaluated the anti-migration activity of SG on CCA cells and its underlined
mechanism.
Methods: CCA cells were treated with SG alone or drugs targeting to epidermal growth factor (EGF) receptor
(EGFR) or pretreated with SG prior to incubation with EGF. Anti-migration activity was determined using a
scratch wound-healing assay and zymography. Immunoﬂuorescence staining and western blotting were used to
investigate EGFR signaling mediators.
Results: Under basal condition, SG reduced the migration rate of CCA, which was correlated with a decrease in
the active-form of matrix metalloproteinases-9. SG decreased expression of phosphorylated focal adhesion kinase
(FAK), but increased expression of E-cadherin to promote cells stasis. Moreover, phosphorylation of EGFR and
extracellular signal-regulated kinases (ERK), known to stimulate growth of cancer cells, was blocked in a
comparable way to EGFR inhibitors Cetuximab and Erlotinib. Pretreatment cells with SG attenuated EGF in-
duced phosphorylation of EGFR, ERK and FAK.
Conclusion: This study reveals that SG from G. ﬁsheri retards migration of CCA cells, and its mechanism of
inhibition is mediated, to some extent, by inhibitory eﬀects on MAPK/ERK signal transduction pathway. Our
ﬁndings suggest that there may be a therapeutic potential of SG in CCA treatment.
Introduction
Cholangiocarcinoma (CCA) arising in the bile duct is associated
with infection of the liver ﬂuke, Opisthorchis viverrini, and endemic in
the Northeastern part of Thailand (Sripa et al., 2011). CCA rates are
high throughout Thailand and Laos and southwestern Vietnam – there
are 20,000 cases of CCA per year, many with metastatic disease, as it
often presents late, despite the recent implementation of screening
programs. CCA patients with metastatic disease are resistant to radia-
tion and chemotherapy and ﬁve-year survival is very low (<2%)
(Benavides et al., 2015). Previous studies have proven that high
malignancy CCA cells are associated with increased levels of matrix
metalloproteinases (MMP) and focal adhesion kinase (FAK)
(Pongchairerk et al., 2005; Hua et al., 2011). Thus, these molecules are
considered as biomarkers of CCA response to treatment as they suppress
CCA migration/invasion. In addition, the mitogen-activated protein
kinases (MAPK)/extracellular signal-regulated kinases (ERK) pathway
has been shown to promote CCA cell invasion (Menakongka and
Suthiphongchai, 2010). Indeed, MMP especially MMP-2 and−9, have a
capacity to degrade collagen, leading to cancer cell migration
(Mook et al., 2004) while FAK promotes cancer cell migration, resulting
in increasing cancer cell invasion (Pongchairerk et al., 2005). E-
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cadherin is considered as a key marker of response to cellular adhesion;
loss of function of this protein has been associated with higher tumor
invasion (Jeanes et al., 2008).
Bioactive polysaccharides from higher plants, seaweeds
(Vishchuk et al., 2011) and mushrooms (Zhang et al., 2012) have de-
monstrated a potential role in cancer therapy in a number of cancer
types. For instance, a polysaccharide from mushrooms Cordyceps si-
nensis signiﬁcantly inhibited breast cancer metastasis and epithelial-
mesenchymal transition (Lin et al., 2016); one from Coriolus versicolor
inhibited migration of mouse mammary carcinoma 4T1 cells by down-
regulating MMP-9 (Luo et al., 2014). Sulfated polysaccharides (SPs)
from brown seaweed inhibited migration of human lung cancer cells by
down-regulating expression of ERK1/2 pathways, leading to decreased
MMP and FAK expression and increased E-cadherin (Lee et al., 2012a).
Moreover, certain polysaccharides have been subjected to early clinical
trials in human (Oba et al., 2007). It is noted that the diﬀerence in
biological activity of polysaccharides is primarily attributed to their
diﬀerent structure or conformation and composition (Mueller et al.,
2000). As such, the search for novel, nontoxic, and eﬀective natural
polysaccharide compounds with multiple anti-cancer activities is a
signiﬁcant goal for anticancer therapy.
Recently, we have extracted sulfated galactans (SG) from red sea-
weed Gracilaria ﬁsheri, a south east Asian seaweed; the structure of SG is
a polysaccharide of galactose backbone and contains a high percentage
of sulfation (Wongprasert et al., 2014). It has been reported that the
polysaccharides of galactose with O-glycosidic linkage and sulfation
provide various potential biological activities such as anti-angiogenic
activity (Liu et al., 2012). We have reported biological activities of SG
including immune stimulating activity (Rudtanatip et al., 2015), and
anti-cancer activity, in particular anti-proliferation (Sae-lao et al.,
2017). In the present study, we tested the hypothesis that SG had the
potential to inhibit migration of CCA cells.
Fig. 1. The eﬀect of SG on HuCCA-1 cell migration by scratch
wound-healing assay. Cells were scratch wounded and then
treated with SG (10, 20, 50 and 100 µg/ml), and photographs
were recorded at 0, 6 and 24 h after scratching. (A) Phase contrast
micrographs showing the size of the scratch wound in diﬀerent
treatment groups compared with control. (B) The distance of
wound closure in HuCCA-1 cells expressed relatively to the initial
gap of control cells in each time point. Results are presented as a
mean± SEM of triplets independent experiments.
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Materials and methods
Sulfated galactans (SG) from Gracilaria ﬁsheri (G. ﬁsheri)
G. ﬁsheri was collected from Surat Thani Province, Thailand, wa-
shed, epiphytes removed, and dried. Dried sample was extracted and
puriﬁed to obtain SG following previously described protocols
(Wongprasert et al., 2014). NMR and FT-IR analysis revealed SG con-
sists of 3-linked-β-D-galactopyranose (G) and 4-linked 3,6-anhydro-α-L-
galactose (LA) or α-L-galactose-6-sulfate (L6S) with partial methylation
(CH3) at C-2 of LA and C-6 of G, and sulfation of C-4 and C-6 of D-
galactose units (G4S and G6S). HPLC analysis of SG showed about 90%
purity.
Cell culture
CCA cells (HuCCA-1 and RMCCA-1) established from CCA tissue
fragments of Thai patients were tested for anti-migration eﬀects of SG.
HuCCA-1 is derived from a patient with intrahepatic bile duct CCA
(Sirisinha et al., 1991). RMCCA-1 is derived from a patient with per-
ipheral CCA (Rattanasinganchan et al., 2006). CCA cells were grown in
6-well plates overnight before treatments. They were cultured at 37 °C,
5% CO2 in Ham F-12 nutrient mixture (Ham F-12) (Gibco Invitrogen,
USA) supplemented with 1mM L-glutamine, 1.17 g/l sodium bicarbo-
nate (NaHCO3), 10% of FBS (Sigma Aldrich, USA) and penicillin
(100 units/ml) plus streptomycin (100 µg/ml) (Wiscent Inc. P.O., Ca-
nada).
Fig. 2. The eﬀect of SG on RMCCA-1 cell migration by scratch
wound-healing assay. Cells were scratch wounded and then
treated with SG (10, 20, 50 and 100 µg/ml), and photographs
were recorded at 0, 6 and 24 h after scratching. (A) Phase contrast
micrographs showing the size of the scratch wound in diﬀerent
treatment groups compared with control. (B) The distance of
wound closure expressed as relatively to the initial gap of control
cells in each time point. Results are presented as a mean± SEM of
triplets independent experiments.
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MTT assay
To examine anti-migration activity of SG, MTT assay was performed
to determine concentrations of SG that would not cause CCA cell death.
HuCCA-1 and RMCCA-1 were grown overnight in a 96-well plate at
density 1×104 cells/well. Cells were incubated with diﬀerent con-
centrations of SG (0, 10, 20, 50 and 100 µg/ml) for 24 h. After in-
cubation cell viability was determined using methyl thiazolium bro-
mide (MTT) assay. Brieﬂy, 100 µl of MTT solution (0.5 mg/ml) (Sigma
Aldrich, USA) was added to each well and incubated for 4 h at 37 °C in
the dark. After incubation, 100 µl of dimethyl sulfoxide (DMSO)
(Merck, Germany) was added to each well, and the absorbance of the
sample was measured at OD 490 nm by a Versamax microplate reader
using SoftMax® Pro 4.8 analysis software (Molecular Devices, USA).
Scratch wound-healing assay
HuCCA-1 and RMCCA-1 cells were seeded at a density of 1×104
cells/well and cultured overnight in 6-well plates. The culture medium
was aspirated and then a sterile pipette tip used to create a scratch
wound, and 5% FBS fresh medium added before treatment with SG (0,
10, 20, 50 and 100 µg/ml). The cells were photographed immediately
and at 6 and 24 h after scratching under a phase-contrast microscope.
The percentage of distance wound closure was measured, using the data
from time 0 (T0), the wound area (Tt: 6 and 24 h) by the following
formula (Kapoor et al., 2008):
= − ×T T
Percentage of distancewound closure
1 (wound area at /wound area at )] 100t 0
MMP-2/−9 activities using zymography
After seeding HuCCA-1 cells overnight, cells in FBS-free culture
medium were scratched by a sterile pipette tip and treated as described
in scratch wound healing assay, and incubated for 12 h. At the desig-
nated time, culture supernatant was collected, lyophilized and protein
concentration was determined. Protein sample (20 µl) was mixed with a
loading dye without dithiothreitol (DTT) (Bio-Rad, USA), loaded into
10% SDS-PAGE gel containing 2% gelatin. The gel was washed twice
with renaturing buﬀer containing 2.5% (w/v) triton X-100, then placed
in zymograph-incubation buﬀer (0.05M Tris buﬀer, pH 7.5 containing
200mM NaCl, 5 mM CaCl2 and 0.05% NaN3) at 37 °C for 18 h. The gel
was stained with 0.5% Coomassie brilliant blue R-250 (Bio-Rad, USA)
in 5% methanol and 10% acetic acid for 2 h and destained with 30%
methanol and 10% acetic acid for 2 h at room temperature (RT). The
MMP activity was quantiﬁed as a percentage of MMP expression com-
pared to the untreated cells. Protein standards were run concurrently,
and approximate molecular weights were determined relative to the
known proteins.
Immunocytochemistry of p-FAK and E-cadherin
HuCCA-1 cells were grown on coverslips in a 24-well plate, and
treatment groups were divided as for the scratch wound-healing assay.
At the designated time, cells grown on coverslips were washed in PBS,
Fig. 3. Dose response curves. HuCCA-1 and RMCCA-1 cells were scratch wounded and
treated with SG (10, 20, 50 and 100 µg/ml) for 24 h incubation. Plot depicts percent of
wound closure vs. SG concentration. The IC50 value for HuCCA-1 was 7 µg/ml, and for
RMCCA-1 was 8 µg/ml (log IC50 0.84 ± 0.34 and 0.9 ± 0.07, respectively).
Fig. 4. MMP activity of HuCCA-1 cells estimated using zymo-
graphy and eﬀect of SG on FAK phosphorylation and E-cadherin
expression in CCA cells. (A) Representative gelatinolytic bands of
MMP-2 and −9 after scratching and treating cells with SG (10
and 50 µg/ml) for 12 h. (B) Relative intensity of the active-form of
MMP-9 was decreased to 86.5 ± 8.11% and 74.5 ± 3.61% of
control. Subsequently, FAK phosphorylation and E-cadherin ex-
pression were determined. HuCCA-1 cells were treated with SG
(10 and 50 µg/ml) for 6 h. (C) The levels of p-FAK and E-cadherin
were analyzed by western blot analysis and α-tubulin protein was
used as a loading control. (D) For SG at 10 and 50 µg/ml, the
relative intensity of p-FAK was decreased to 0.75 ± 0.04 and
0.63 ± 0.06 fold of control, respectively whereas E-cadherin was
increased to 2.5 ± 0.36 and 3.3 ± 0.41 fold of control. Results
are presented as a mean ± SEM of triplets of independent ex-
periments; * (p<.05) indicates signiﬁcantly diﬀerent from con-
trol.
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pH 7.4 and ﬁxed with 4% paraformaldehyde in PBS, pH 7.4 for 10min.
HuCCA-1 cell membranes were permeabilized with 0.1% Triton X-100
in PBS (PBS-T) for 3–5min, blocked with PBS and 3% bovine serum in
PBS-T for 2 h, then incubated with anti-p-FAK or anti-E-cadherin anti-
bodies or without primary antibodies (all at 1:500) (Cell Signaling
Technology, USA) in blocking solution, at 4 °C overnight in the dark
moist chamber. Cells were incubated with goat anti-rabbit IgG-CFL555-
conjugated secondary antibody (1:1000) (Cell Signaling Technology,
USA) in PBS-T for 1 h, counterstained with 1 µg/ml DAPI (Sigma
Aldrich, USA) for 5–10min, and examined under a confocal laser
scanning microscope (FV10i-DOC, Olympus, Japan).
Western blot analysis
HuCCA-1 cells were grown in 6-well plates (1× 106 cells/well), for
24 h. Cells underwent a scratch wound-healing assay. Cells were treated
with SG (10 and 50 µg/ml) or EGFR inhibitors (Cetuximab, 100 µg/ml,
Merck, Germany; Erlotinib, 5 µM, Selleckchem, Texas, USA) or EGF
(20 ng/ml, cell signaling Technology, USA) or pretreated with SG prior
to incubation with EGF. Cells were then collected and cell lysates were
prepared in lysis buﬀer (3 mM MgCl2, 1 mM EGTA, 10mM sodium
pyrophosphate (NaPpi), 10 mM sodium orthovanadate (Na3VO4),
50mM sodium ﬂuoride (NaF) and 100 X protease inhibitor solution)
and centrifuged at 8500× g for 15min at 4 °C. The supernatant was
collected to determine protein concentration by BCA assay using the
Pierce™ BCA Protein Assay Kit (Thermo Scientiﬁc, USA). Proteins were
separated on 10–12.5% gel SDS-PAGE, blotted onto a nitrocellulose
membrane (Merck, Germany), and incubated with primary antibodies: -
p-FAK, E-cadherin (Cell Signaling Technology, USA), EGFR, phos-
phorylated-EGFR (p-EGFR), and phosphorylated-ERK (p-ERK) anti-
bodies (Santa Cruz Biotechnology, USA), followed by incubation with
horseradish-peroxidase-conjugated (HRP) secondary antibody. Anti-
alpha (α)-tubulin antibody (Santa Cruz Biotechnology, USA) was also
probed in all blots as an internal control. Proteins were detected using
the Enhanced Chemiluminescence (ECL) kit (GE Healthcare, UK) and
visualized on Hyperﬁlm ECL (Piscataway, USA). Expression of protein
was quantiﬁed by ImageJ analysis program (from NIH website by Scion
Corporation, Frederick, MD).
Statistical analysis
All methods were performed in triplicate. Data are presented as
Fig. 5. Immunoﬂuorescent micrographs showing lo-
calization of p-FAK in HuCCA-1 cells underwent
scratched wounded and treated with or without SG
for 24 h. (A–C) Cells omitted anti p-FAK primary
antibody. (D–F) Control cells cultured with normal
media. (G–I) cells treated with 10 µg/ml SG. (J–L)
Cells treated with 50 µg/ml SG. The primary anti-
body was anti p-FAK antibody and the secondary
antibody was CFL555-conjugated secondary anti-
body (red). Nuclei were counterstained with DAPI
(blue). Scale bars= 10 µm. (For interpretation of the
references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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means± SEM and statistically analyzed by one-way analysis of var-
iance (ANOVA) followed by Turkey's multiple comparison tests and
two-way ANOVA in GraphPad Prism program version 6 (GraphPad
software, USA). Diﬀerence with p-values less than 0.05 were considered
statistically signiﬁcant. IC50 were calculated from a least squares ﬁt of
normalized data to a four-parameter inhibitor non-linear curve ﬁt
(Prism 7.0).
Results
SG retarded the migration of CCA cells
The MTT assay showed that SG at the tested concentrations (0, 10,
20, 50 and 100 µg/ml) did not induce CCA cell death. In addition, cells
maintained normal morphology after treatment (data not shown).
Therefore, these doses of SG were further employed for investigating
the eﬀect of SG on CCA cell migration.
The HuCCA-1 and RMCCA-1 cell lines were treated with the scratch
wound, followed by treatment with SG (0, 10, 20, 50 and 100 µg/ml).
The phase contrast micrographs revealed that at 24 h after scratching
SG dose dependently retarded the migration of HuCCA-1 (Fig. 1A) and
RMCCA-1 cells (Fig. 2A) compared with control. For HuCCA-1 cells, the
distance of wound closure at 6 and 24 h after scratching in the control
cells were 44.3 ± 5.84 and 95.9 ± 4.02% of the initial gap, respec-
tively. While cell treatment with SG at concentrations of 10, 20, 50 and
100 µg/ml the distance of wound closure at 6 h were 33.3 ± 9.03,
29.7 ± 7.62, 16.9 ± 1.81, and 9.3 ± 1.33% of the initial gap, re-
spectively, and at 24 h were 63.8 ± 11.36, 50.1 ± 12.06,
47.4 ± 12.68, and 40.6 ± 10.91% of the initial gap, respectively
(Fig. 1B).
For RMCCA-1 cells, the distance of wound closure at 6 and 24 h after
scratching in the control cells were 38.2 ± 3.99 and 62.4 ± 5.34% of
the initial gap, respectively. While cell treatment with SG at con-
centrations of 10, 20, 50 and 100 µg/ml, the distances of wound closure
at 6 h were 34.5 ± 4.41, 16.4 ± 0.82, 19.08 ± 1.16, and
19.07 ± 1.58% of the initial gap, respectively, and at 24 h were
48.7 ± 5.02, 25.9 ± 7.75, 25.4 ± 2.99, and 21.1 ± 3.01% of the
initial gap, respectively (Fig. 2B). The IC50 for HuCCA-1 was 7 µg/ml
and for RMCCA-1 was 8 µg/ml (log IC50 0.844 ± 0.34 and 0.9 ± 0.07,
respectively (Fig. 3)).
Fig. 6. Immunoﬂuorescent micrographs showing lo-
calization of E-cadherin in HuCCA-1 cells underwent
scratched wounded and treated with or without SG
for 24 h. (A–C) Cells omitted anti-E-cadherin primary
antibody. (D–F) Control cells cultured with normal
media. (G–I) cells treated with 10 µg/ml SG. (J–L)
Cells treated with 50 µg/ml SG. The primary anti-
body was anti E-cadherin antibody and the sec-
ondary antibody was CFL555-conjugated secondary
antibody (red). Nuclei were counterstained with
DAPI (blue). Scale bars= 10 µm. (For interpretation
of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
T. Sae-lao et al. Phytomedicine 36 (2017) 59–67
64
SG decreased the active-form of MMP-9 activity in HuCCA-1 cells
MMP activity of HuCCA-1 cells after SG treatment was analyzed by
zymography. The results showed that HuCCA-1 cell treatment with SG
at doses of 10 and 50 µg/ml decreased the amount of the active-form of
MMP-9 to 86.5 ± 8.11 and 74.5 ± 3.61% of control, respectively
(Fig. 4A, B) whereas the MMP-2 activity was not diﬀerent from control
cells.
SG down-regulated the expression of p-FAK and up-regulated the expression
of E-cadherin proteins
The eﬀect of SG on p-FAK and E-cadherin, molecules known to
regulate the cell migration process, was determined in HuCCA-1 cells
after a scratch wound assay. The results showed that treating HuCCA-1
cells with SG (10 and 50 µg/ml) signiﬁcantly decreased expression of p-
FAK to 0.75 ± 0.04 and 0.63 ± 0.06 fold of control, respectively, and
increased expression of E-cadherin to 2.5 ± 0.36 and 3.3 ± 0.41 fold
of control, respectively (Fig. 4C, D). Levels of p-FAK and E-cadherin
were also determined from images from immuno-stained cells. The
results demonstrated that HuCCA-1 cell treatment with SG showed
substantially less immunoreactivity of p-FAK (Fig. 5) and more im-
munoreactivity of E-cadherin compared with control cells (Fig. 6).
SG suppressed HuCCA-1 cell migration by down-regulating signaling
molecules in EGFR/MAPK/ERK pathway
Our ﬁndings showed that SG inhibited HuCCA-1 cells migration by
regulating p-FAK, E-cadherin expression, and MMP-9 activity. A
number of ﬁndings have revealed that the MAPK/ERK signal trans-
duction pathway regulates CCA cell migration and invasion
(Menakongka and Suthiphongchai, 2010). The pathway is activated
through surface receptors such as EGFR that consequently activate
downstream ERK phosphorylation. We thus examined the manipulation
of SG on these molecules in this pathway. The results showed that
treating HuCCA-1 cells for 6 h with SG alone (10 and 50 µg/ml) did not
signiﬁcantly alter basal EGFR expression (Fig. 7A) but showed marked
inhibition of p-EGFR compared to control. The ratio of p-EGFR/EGFR
expression decreased to 0.75 ± 0.02, and 0.68 ± 0.03 fold of control,
respectively. Expression of the downstream signaling molecules of
EGFR, p-ERK and p-FAK were also down-regulated (p-ERK:
0.47 ± 0.01 and 0.39 ± 0.03 fold of control; p-FAK: 0.84 ± 0.02 and
0.69 ± 0.02 fold of control, respectively) (Fig. 7A, B). We next de-
termined whether SG could suppress EGF induced EGFR activation by
pretreating the cells with SG for 6 h prior to incubation with EGF for
2 h. The results showed that EGF stimulated overexpression of p-EGFR/
EGFR followed by increased activation of downstream signaling p-ERK
and p-FAK (1.17 ± 0.01, 1.35 ± 0.01, and 1.23 ± 0.03 fold of con-
trol, respectively). However, these events were markedly inhibited by
pretreating the cells with SG (10 and 50 µg/ml) in a dose dependent
manner (p-EGFR/EGFR: 0.85 ± 0.04 and 0.74 ± 0.09 fold of control;
p-ERK; 0.77 ± 0.03 and 0.56 ± 0.04 fold of control; p-FAK:
0.92 ± 0.02 and 0.84 ± 0.02 fold of control, respectively) (Fig. 7A,
B). These results suggest that SG inhibited EGFR activation and signal
transduction. The eﬀects of the two EGFR inhibitors, the monoclonal
antibody against EGFR Cetuximab and the tyrosine kinase inhibitor
Erlotinib were also tested on HuCCA-1 cells. Treating the cells with the
Fig. 7. Eﬀect of SG on the expression of EGFR/MAPK/ERK downstream signaling protein
in HuCCA-1 cells. (A, B) The representative immunoblots and relative intensity of sig-
naling proteins in control cells, cells treated with SG for 6 h, cells pretreated with SG for
6 h followed with EGF for 2 h. EGF stimulated increased expression of p-EGFR/EGFR, p-
ERK and p-FAK. Cells treated with either SG alone or pretreating with SG prior to EGF
showed down-regulation of p-EGFR/EGFR, p-ERK and p-FAK from control. Results are
presented as a mean ± SEM of three independent experiments; * (p< .05) indicates
signiﬁcantly diﬀerent from control. # (p< .05) indicates signiﬁcantly diﬀerent from EGF
treated group.
Fig. 8. Eﬀect of drugs targeting EGFR (Cetuximab or Erlotinib) on
the expression of EGFR/MAPK/ERK downstream signaling pro-
tein in HuCCA-1 cells. (A, B) The representative immunoblots and
relative intensity of signaling proteins in control cells, cells
treated with Cetuximab or Erlotinib for 6 h. The results revealed
that HuCCA-1 cells treated with Cetuximab or Erlotinib showed
down-regulation of p-EGFR/EGFR, p-ERK and p-FAK from con-
trol. Results are presented as a mean ± SEM of three in-
dependent experiments; * (p< .05) indicates signiﬁcantly dif-
ferent from control.
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Cetuximab or Erlotinib for 6 h caused a similar down regulation of p-
EGFR/EGFR, p-ERK and p-FAK (Cetuximab: p-EGFR/EGFR,
0.88 ± 0.02 fold of control; p-ERK, 0.83 ± 0.04 fold of control; p-
FAK, 0.77 ± 0.02 fold of control while Erlotinib: p-EGFR/EGFR,
0.83 ± 0.01 fold of control; p-ERK, 0.80 ± 0.03 fold of control; p-
FAK, 0.68 ± 0.02 fold of control) (Fig. 8A, B).
Discussion
Cholangiocarcinoma (CCA) is a rare and devastating malignancy,
and the incidence of CCA has increased worldwide with a very poor
prognosis due to their resistance to radiotherapy and chemotherapy
(Zografos et al., 2011). Current cancer treatments are moving towards
agents more speciﬁcally targeting the tumor drivers and ways to inhibit
these drivers. To date, interesting approaches include strategies tar-
geting the EGFR family and the mitogen-activated protein kinases,
(MAPK) signaling cascade. The RAS/RAF/MEK/ERK tyrosine kinases
pathway is frequently dysregulated in cancers, including CCA, pro-
moting cancer cell growth and survival (O'Neill and Kolch, 2004).
Sulfated polysaccharides (SPs), the complex and heterogeneous mac-
romolecules found at high concentrations in seaweed, have shown anti-
cancer activity against various cancer cell types (Zhang et al., 2011).
Many natural SPs have structure similar to heparan sulfate proteogly-
cans (HSPGs) and imitate the function of HSPGs (Zhang et al., 2010).
They can bind to growth factor/receptor and co-receptors, resulting in
suppression of the activation of receptor downstream signaling path-
ways (Lee et al., 2008a). Previously, we isolated sulfated galactans (SG)
from G. ﬁsheri and found its structure similar to HSPGs. SG inhibit
proliferation of human cholangiocarcinoma cells, HuCCA-1 by inter-
acting with EGFR and inactivating EGFR signaling. In this study we
aimed to determine whether there was an anti-migration eﬀect of SG on
human cholangiocarcinoma cells in particular through the RAS/RAF/
MEK/ERK signaling system.
Our study revealed that SG was able to retard the migration rates of
two diﬀerent CCA cell lines, HuCCA-1 and RMCCA-1 cells. HuCCA-1 is
moderately invasive (Sirisinha et al., 1991) while RMCCA-1 is a low
invasive CCA (Rattanasinganchan et al., 2006). We further evaluated
the underlined anti-migration eﬀect of SG on HuCCA-1 cells. Move-
ments of cancer cells are mostly regulated by matrix metalloproteinases
(MMP), especially MMP-2 and MMP-9 to degrade the collagen com-
ponents of extracellular matrix. High level of MMP expression is im-
portant for CCA migration and indicates a more severe invasiveness of
cancer cells (Fava, 2010). Cell treatment with SG attenuated activity of
the active form of MMP-9 and restored the pro-form of MMP. These
eﬀects of SG on MMP have also been reported in human bladder cancer
cells (Cho et al., 2014).
Focal adhesion kinase (FAK) and E-cadherin are important mole-
cules working in opposite ways to promote cancer cell migration. FAK
up-regulation enhances cell motility whereas E-cadherin down-regula-
tion occurs during cancer cell migration (Schaller, 2001). It is evi-
denced that EGFR activation by EGF up-regulates EGFR phosphoryla-
tion and downstream signaling molecules such as ERK and PI3K/AKT.
Indeed, ERK is a downstream eﬀector of FAK and E-cadherin (Bae et al.,
2013). Our results revealed that HuCCA-1 cells constitutively expressed
p-EGFR and p-FAK. At basal level, SG could inhibit EGFR and FAK
phosphorylation and stimulated expression of E-cadherin, which cor-
responded to a decrease in HuCCA-1 cells migration rate and correlated
with the decrease in expression of MMP-9. Consistent with previous
studies, SPs from sea cucumber inhibited migration of gastric adeno-
carcinoma cell lines (Tian et al., 2005) and pancreatic cell lines
(Shimizu et al., 2013) by suppressing phosphorylation of FAK. In ad-
dition, SPs from the cuttleﬁsh ink induced E-cadherin expression
(Zong et al., 2013).
The MAPK/ERK pathway is among the key mechanisms that
transmit signals upon receptor activation from the cell surface to nu-
cleus, eliciting proliferative and migration signals in cancer cells.
Indeed, EGF binds to EGFR then stimulates ERK phosphorylation (p-
ERK), which then translocates to the nucleus, where p-ERK stimulates
several nuclear targets including FAK, MMP, and E-cadherin and pro-
motes migration of tumor cells (Sun et al., 2015). It has been reported
that activation of the MAPK/ERK pathway promotes CCA cell invasion
(Menakongka and Suthiphongchai, 2010). We, therefore, examined
whether the anti-migration activity of SG in HuCCA-1 cells was due to
inhibition of ERK phosphorylation, a major driver of cancer cell mi-
gration. Our study showed that SG down-regulated basal p-EGFR and p-
ERK while the expression of EGFR remained unchanged. These results
suggest that SG showed inhibitory eﬀect on EGFR activation not on
EGFR expression. In agreement with previous study, fucoidan, SP ex-
tracted from brown seaweed suppressed the EGF-induced the expres-
sion of p-EGFR and p-ERK1/2 but did not alter the EGFR level in normal
mouse epidermal cells (Lee et al., 2008b). Moreover, SG showed a
potent inhibitor against exogenous EGF induced EGFR activation and
its downstream signaling to p-ERK, as shown that it suppressed ex-
pressions of p-FAK and p-ERK which levels were less than control un-
treated cells.
EGFR is overexpressed in all types of CCA (Yoshikawa et al., 2008).
EGFR targeted drugs have been tested in CCA clinical trials including
Cetuximab and Erlotinib. Cetuximab is a chimeric monoclonal antibody
which blocks binding of EGF and TGFα to the EGFR. Erlotinib is an
active tyrosine kinase inhibitor of EGFR. They both inhibit EGFR acti-
vation and its downstream signaling pathway proteins (Goldstein et al.,
1995; Gordon et al., 2005). Our study showed that HuCCA-1 cells were
sensitive to both Cetuximab and Erlotinib, an eﬀect comparable to SG
treatment. However, previous phase II clinical trials showed that ad-
vanced CCA patients had a low responsiveness to a single Cetuximab
(Philip et al., 2006) or Erlotinib treatments (Sprinzl et al., 2006). Sa-
tisfactory CCA treatments were mostly accomplished by combined drug
treatments. For instance, combination of Cetuximab with GEMOX
(Gemcitabine plus Oxaliplatin) (Gruenberger et al., 2010) or Erlotinib
with GEMOX provided more eﬀective treatments in advanced or poor
prognosis CCA patients (Lee et al., 2012b).
In conclusion, the present study suggests that SG from G. ﬁsheri can
reduce HuCCA-1 cell migration, possibly by inhibiting EGFR and ERK
phosphorylation in EGFR/MAPK/ERK signaling pathway similar to the
eﬀect of the EGFR inhibitors Cetuximab and Erlotinib. This inhibiting
activity of SG provides a signiﬁcance application as an adjuvant for
enhancing eﬀectiveness in treatment to prevent cancer recurrence or
metastasis, in particular those associated with ERK.
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